State pre-emption law challenged by US Supreme Court verdict?
The US Supreme Court's verdict in the Wyeth versus Levine case, which decided by six votes to three that federal regulation of drug labeling safety by the Food and Drug Administration does not pre-empt state tort law (Marketletter March 9), has been seized upon by critics of the state of Michigan's own legislation, which prevents patients from suing drugmakers.
According to Douglas Peters, a trial lawyer at Detroit-based law firm Charfoos & Christensen, "this decision may have a sobering impact on the Republicans in the Michigan Senate, which should immediately consider reversing Michigan's unique and unfair law to bring Michigan back into line with the law of the other 49 states, as recognized by the US Supreme Court in its new decision."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze